In Depth Research on Global Breast Cancer Monoclonal Antibodies Market Outlook 2020

" Global Breast Cancer Monoclonal Antibodies Market Outlook 2020" Report Highlights:

* Breast Cancer Monoclonal Antibodies Mechanism
* Global Breast Cancer Monoclonal Antibody Market Analysis
* Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
* Breast Cancer Monoclonal Antibodies Pipeline: 62 mAb
* Majority Breast Cancer Monoclonal Antibodies in Preclinical Phase: 17 mAb
* Marketed Breast Cancer Monoclonal Antibodies: 6 mAb

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-Global-Breast-Cancer-Monoclonal-Antibodies-Market-Outlook-2020.php

Table of Contents

1. Introduction to Monoclonal Antibodies
1.1 History of Development of Monoclonal Antibodies
1.2 Working of Monoclonal Antibodies

2. Need for Monoclonal Antibodies for Cancer Treatment

3. Breast Cancer Monoclonal Antibodies Mechanism

4. Global Breast Cancer Monoclonal Antibody Market Analysis
4.1 Current Market Scenario
4.2 Breast Cancer Pipeline Overview

5. Global Breast Cancer Monoclonal Antibody Market Dynamics
5.1 Favorable Market Parameters
5.2 Commercialization Challenges

6. Global Breast Cancer Monoclonal Antibodies Market Future Prospects

7. Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
7.1 Unknown
7.2 Research
7.3 Preclinical
7.4 Clinical
7.5 Phase I
7.6 Phase I/II
7.7 Phase II
7.8 Phase III
7.9 Registered

8. Marketed Breast Cancer Monoclonal Antibodies Clinical Insight
8.1 Bevacizumab (Avastin®)
8.2 Pertuzumab (Omnitarg, Perjeta®)
8.3 Trastuzumab (Herceptin®)
8.4 Trastuzumab Biosimilar (Hertraz™ & CANMAb™)
8.5 Trastuzumab Emtansine (Kadcyla®)
8.6 Trastuzumab Subcutaneous (Herceptin®)

9. Discontinued & Suspended Breast Cancer Monoclonal Antibodies Pipeline by Company & Phase
9.1 Discontinued
9.2 No Development Reported

10. Competitive Landscape
10.1 Amgen
10.2 Biocad
10.3 Biocon
10.4 Celltrion Pharm
10.5 CuraGen Corporation
10.6 Dyax Corp
10.7 GlaxoSmithKline
10.8 ImmunoGen
10.9 MacroGenics
10.10 Merck
10.11 Merrimack Pharmaceuticals
10.12 Novartis
10.13 Pierre Fabre
10.14 Pfizer
10.15 Recombio
10.16 Roche Holding
10.17 Samsung Bioepis
10.18 Synthon

Figure 1-1: History of Development of Monoclonal Antibodies
Figure 1-2: Working of Monoclonal Antibodies
Figure 3-1: Mechanism of Bevacizumab
Figure 3-2: Mechanism of Denosumab
Figure 3-3: Mechanism of Trastuzumab
Figure 3-4: Mechanism of Trastuzumab Emtansine
Figure 3-5: Mechanism of Pertuzumab
Figure 4-1: Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-2: Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-3: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-4: No Development Reported Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 4-5: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (%), 2015
Figure 4-6: Discontinued Breast Cancer Monoclonal Antibodies Pipeline by Phase (Numbers), 2015
Figure 5-1: Global Breast Cancer Monoclonal Antibody Market Favorable Parameters
Figure 5-2: Breast Cancer Monoclonal Antibodies Commercialization Challenges
Figure 10-1: Amgen Clinical Pipeline
Figure 10-2: Biocon Clinical Pipeline
Figure 10-3: Celltrion Clinical Pipeline
Figure 10-4: MacroGenics Clinical Pipeline
Figure 10-5: Novartis Clinical Pipeline
Figure 10-6: Synthon Clinical Pipeline

Table 2-1: Breast Cancer Monoclonal Antibodies Available in Global Market
Table 2-2: Herceptin Biosimilars Available in Global Market

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.